Effects of intermittent fasting regimens on glycemic, hepatic, anthropometric, and clinical markers in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis of randomized controlled trials
Saleh SAK, Santos HO, Găman MA, Cerqueira HS, Zaher EA, Alromaih WR, Arafat NS, Adi AR, Adly HM, Alyoubi R, Alyahyawi N, Kord-Varkaneh H
Clinical nutrition ESPEN · 22 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2023-11-27 · Clin Nutr ESPEN · vol. 59 · págs. 70–80
- Editorial
- Elsevier BV
- Citado
- 28 citas · más que el 80% de estudios similares · 1.4× el promedio de su campo
- Referencias
- 55 trabajos
- Acceso
- De pago
- Áreas de investigación
- Dietary Effects on Health · Liver Disease Diagnosis and Treatment · Enhanced Recovery After Surgery
- Palabras clave
- intermittent fasting, non-alcoholic fatty liver disease, 5:2 diet, time-restricted feeding, alternate-day fasting, hepatic steatosis, alanine aminotransferase, triglycerides, cholesterol, HbA1c, insulin resistance, obesity, body mass index, waist circumference, cardiometabolic biomarkers, liver function markers, weight loss
- MeSH
- humans, cardiovascular diseases, randomized controlled trials as topic, non-alcoholic fatty liver disease, biomarkers, intermittent fasting
12 autores
- Saleh A. K. Saleh🇪🇬🇸🇦Ain Shams University; Umm al-Qura University
- Heitor Oliveira Santos🇧🇷Universidade Federal de Uberlândia
- Mihnea‐Alexandru Găman🇷🇴Carol Davila University of Medicine and Pharmacy; Institutul Clinic Fundeni
- Henrique Santa Capita Cerqueira🇧🇷Universidade de São Paulo
- Eman Abbas Zaher🇸🇦King Abdulaziz Medical City
- Wafa Romaih Alromaih🇸🇦King Abdulaziz Medical City
- Norah Saud Arafat🇸🇦Security Forces Hospital
- Abdul Rahman Adi🇸🇦Alfaisal University
- Heba Mohamed Adly🇸🇦Umm al-Qura University
- Reem Abdullah Alyoubi🇸🇦King Abdulaziz University; King Abdul Aziz University Hospital; King Abdulaziz Hospital
- Naseem Y. Alyahyawi🇸🇦King Abdulaziz University; King Abdul Aziz University Hospital; King Abdulaziz Hospital
- Hamed Kord‐Varkaneh🇮🇷 · autor de correspondenciaHamedan University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
Intermittent fasting (IF) regimens have been hypothesized to influence several markers of cardiometabolic and liver function. The objective of our meta-analysis was to investigate the impact of IF regimens on cardiometabolic and liver markers in subjects diagnosed with non-alcoholic fatty liver disease (NAFLD).
Methods
We searched several online databases (PubMed/Medline, Web of Science, Scopus and Embase) in order to identify suitable publications for inclusion in the meta-analysis. Results were expressed as weighted mean differences (WMD).
Results
From 12343 articles identified in different databases, a total of 7 RCT arms were entered into the quantitative synthesis. The manuscripts were published between 2019 and 2023. IF regimens (the 5:2 diet, 16/8 time-restricting feeding, and alternate day fasting) varied from 2 months to 3 months. IF regimens reduced steatosis scores (WMD: -33.22 CAP dB/m, 95 % CI: -50.72 to -15.72), anthropometric characteristics of obesity (WMD: -0.77 kg/m2, 95 % CI: -1.38 to -0.17 for body mass index; WMD: -3.16 kg, 95 % CI: -4.71 to -1.61 for body weight; WMD: -1.90 kg, 95 % CI: -3.51 to -0.29 for waist circumference), as well as ALT (WMD: -9.10 U/L, 95 % CI: -12.45 to -5.75), triglyceride (WMD: -20.83 mg/dl, 95 % CI: -39.01 to -2.66), total cholesterol (WMD: -7.80 mg/dl, 95 % CI: -15.18), HbA1c (WMD: -0.14 %, 95 % CI: -0.20 to -0.08) and HOMA-IR (WMD: -1.21, 95 % CI: -2.08 to -0.34) levels versus controls. Nevertheless, no between-group differences were detected for other biomarkers, e.g., fasting blood glucose, insulin, AST, HDL-C or LDL-C values, and fibrosis scores.
Conclusion
IF regimens can improve some markers of cardiometabolic and liver function in patients with NAFLD. However, the available evidence to support the benefits of IF regimens is limited and derived from a small number of studies, thus further research is needed to clarify the impact of IF on the cardiometabolic health of NAFLD patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.